|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse.
|
19781322 |
2009 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
The clinical significance of these results is stressed by the finding that NCoR and TRβ transcripts correlate negatively with those of the lymphangiogenic genes and the lymphatic vessel marker LYVE-1 in human breast tumors.
|
27806339 |
2016 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
LHGDN |
Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
|
15802375 |
2005 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.
|
30485330 |
2018 |
|
Liver neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.
|
27064257 |
2016 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Anxiety Disorders
|
0.200 |
Biomarker
|
group |
RGD |
The nuclear receptor corepressor has organizational effects within the developing amygdala on juvenile social play and anxiety-like behavior.
|
20051490 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PDCD2 and NCoR1 as putative tumor suppressors in gastric gastrointestinal stromal tumors.
|
26589942 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor analysis revealed two mutations: a TP53 missense mutation c.481G>A (p. Ala161Tyr) and NCOR1 nonsense mutation c.6052C>T (p. Arg2018*).
|
30039904 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, hereby we describe the presence and prognostic role of mutations in the NCOR1 gene in hormone receptor negative breast and lung adenocarcinomas, and we also confirm that NCOR1 is a tumor suppressor gene.
|
30485330 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of the exosomal content identified miR-1587 as a mediator of the exosomal effects on GSCs, in part via downregulation of the tumor-suppressive nuclear receptor corepressor NCOR1.
|
28855213 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed the expression of NCOR1 in two independent cohorts and demonstrated that NCOR1 is a tumor suppressor and has prognosis potential in lung squamous carcinomas.
|
31661545 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, we have analyzed the subcellular localization of N-CoR in 43 colorectal cancer samples and we have found that aberrant cytoplasmic distribution of N-CoR is a general trait of these tumors.
|
17630505 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we show that PML interacts with multiple corepressors (c-Ski, N-CoR, and mSin3A) and histone deacetylase 1, and that this interaction is required for transcriptional repression mediated by the tumor suppressor Mad.
|
11430826 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The thyroid hormone receptor TRβ increases NCoR expression and this induction is essential in mediating the anti-metastatic and tumor suppressive actions of the receptor.
|
27149915 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Similarly, 10/15 primary tumour cultures (including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated.
|
15300237 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It was found that NCOR1 mRNA was expressed at significantly higher levels in patients over 50 years of age, without axillary lymph node involvement, with tumor size less than 2 cm, with low or intermediate histological grade, with ERalpha/PgR-positive and with HER2 negative tumors.
|
16019133 |
2006 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Since metastasis is the main cause of cancer-related deaths, these results define NCoR as a potential target for cancer therapy.
|
27149915 |
2016 |
|
Malignant Neoplasms
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
This binding inhibited colocalization of N-CoR/HDAC3, thereby inhibiting deacetylation of histones and HDAC4 client transcription factors, such as HIF-1α, which are bound at promoter/enhancers where epigenetic reprogramming is required for cancer cell survival and angiogenic response.
|
23149916 |
2013 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Reduction in NCOR1 levels causes bicalutamide resistance in LNCaP cells and compromises response to bicalutamide in mouse prostate in vivo Clin Cancer Res; 22(15); 3937-49.©2016 AACR.
|
26968201 |
2016 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Since metastasis is the main cause of cancer-related deaths, these results define NCoR as a potential target for cancer therapy.
|
27149915 |
2016 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Reduction in NCOR1 levels causes bicalutamide resistance in LNCaP cells and compromises response to bicalutamide in mouse prostate in vivo Clin Cancer Res; 22(15); 3937-49.©2016 AACR.
|
26968201 |
2016 |
|
Primary malignant neoplasm
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
This binding inhibited colocalization of N-CoR/HDAC3, thereby inhibiting deacetylation of histones and HDAC4 client transcription factors, such as HIF-1α, which are bound at promoter/enhancers where epigenetic reprogramming is required for cancer cell survival and angiogenic response.
|
23149916 |
2013 |
|
Colorectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Aberrant cytoplasmic localization of N-CoR in colorectal tumors.
|
17630505 |
2007 |
|
Lung Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In our article, by using an in silico approach, we evaluate the mutational status of NCOR1 in breast and lung tumors.
|
30485330 |
2018 |